DSCSA data exchange has matured into daily operations, but the coming NDC-12 shift and a national licensure standard add new work streams before old ones are fully settled.
News|Articles|August 3, 2026
FAQ: Pharma's July 31 Tariff Deadline Has Passed. Now What?
Author(s)Stephen Appezzato
The Section 232 tariff deadline for 17 major drugmakers has arrived. Here's what pharma supply chain teams need to know now.
Advertisement
Advertisement
The Section 232 pharmaceutical tariff regime is no longer a future date on the calendar. As of July 31, 2026, it's active law for the industry's largest manufacturers, with a second deadline and a separate generics timeline still ahead. Here's what changed and what to watch next.
Related to this article
As HRSA's 340B Rebate Model Pilot moves toward its effective date, Valerie Bandy, PharmD, of Tecsys explains what drug-by-drug rebate tracking really demands from hospital and health system pharmacies.
Twenty-six manufacturers now hold most-favored-nation agreements, and the commitments attached to the pricing terms may matter more than the prices themselves.
Cencora's Ameer Ali explains why trading partners' systems, not the NDC-12 deadline itself, determine whether product keeps moving through the supply chain during the transition.
Nine more manufacturers join the MFN program, pairing new Medicaid pricing deals with $19.6B in U.S. manufacturing investment and API reserve donations.
Go behind the scenes of LogiPharma USA 2026 with program director Charleen Ring and McKesson's Chris Van Norman in this Pharma Pulse special.
Gregg Gorniak explains how AI, RFID and serialized data are helping trading partners move DSCSA compliance from a regulatory checkbox to a source of shared operational value.
Authenticx CEO Amy Brown on why patient support AI needs continuous oversight, not just adoption.
Advertisement
Advertisement